Eccrine Neoplasm — knowledge graph · CancerIndex

Knowledge graph · Cancer

Eccrine Neoplasm

subtype

Identifier: CI-CAN-00002575
Entity page: /cancer/eccrine-neoplasm ↗
Edges: 12

Neighbours: 4 drugs8 trials
Drawn: 12 of 12 neighbours (cap 60); table lists every fetched edge

Accepted: cancer:<slug>, gene:<symbol>, variant:<slug>, drug:<slug>, trial:<NCT id>, or a bare CI id. Find slugs with search.

Most connectedLung Non-Small Cell Carcinoma 3,147 Malignant Colorectal Neoplasm 1,866 ABL1 298 EGFR 276 Imatinib 450 Dasatinib 321

Neighbourhood

Radial view

Focus at the centre; neighbours grouped by entity type. Click a node to re-centre the graph on it; ↗ opens the entity page. Hover a spoke for relationship, evidence level, cancer context and source.

Edges

Every edge, grouped by relationship

Source-native edges first (aggregated per neighbour, direction, evidence level and source), then derived registry links. Up to 15 per relationship (10 trials); “show all” raises one group to 200.

Relationship	Neighbour	Direction	Evidence level	Cancer context	Support	Claim	Source	Expand
Eccrine Neoplasm investigated in trials for …INVESTIGATED_IN_TRIALSderived4 of 4
→ investigated in trials for	Imatinib Mesylatesmall molecule 2 trials (0 active) · roll-up of the cancer and its descendants	—	—	Eccrine Neoplasm	2	Observed	clinicaltrials	graph →
→ investigated in trials for	Nilotinibsmall molecule 1 trials (0 active) · roll-up of the cancer and its descendants

Eccrine Neoplasm studied in …STUDIED_INderived8 of 8
→ studied in	NCT02978625Phase 2 · active not recruiting Talimogene Laherparepvec and Nivolumab in Treating Patients With Refractory Lymphomas or Advanced or Refractory Non-melanoma Skin Cancers · condition mapped ONTOLOGY_EXACT · 8 trials mapped (4 active)	—	—	Digital Papillary Adenocarcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT07301424Phase 2 · not yet recruiting Subcutaneous Blinatumomab Plus Ponatinib for BCR-ABL+ B-ALL · condition mapped ALIAS · 8 trials mapped (4 active)	—	—	Poroid Hidradenoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT07152041Phase 3 · recruiting Newly-diagnosed Pediatric Ph-positive B-ALL Protocol · condition mapped ALIAS · 8 trials mapped (4 active)	—	—	Poroid Hidradenoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT05797415recruiting Sentinel Lymph Node Biopsy in Ocular Surface and Adnexal Cancers · condition mapped ONTOLOGY_EXACT · 8 trials mapped (4 active)	—	—	Porocarcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT01131325Phase 4 · terminated Study of Nilotinib in Ph+ CML-CP Patients With Low Imatinib Trough Plasma Concentrations · condition mapped ALIAS · 8 trials mapped (4 active)	—	—	Poroid Hidradenoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT03647631completed Sentinel Lymph Node Biopsy in Porocarcinoma · condition mapped ONTOLOGY_EXACT · 8 trials mapped (4 active)	—	—	Porocarcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT01221376Phase 2 · unknown Phase II Study for Safety and Efficacy Evaluation of Imatinib Mesylate in Children With Chronic Myeloid Leukemia (CML) Philadelphia Chromosome-positive (Ph+) · condition mapped ALIAS · 8 trials mapped (4 active)	—	—	Poroid Hidradenoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT01222013Phase 2 · suspended Study for Safety and Efficacy Evaluation of Imatinib Mesylate in Children With Acute Lymphoblastic Leukemia (ALL) Philadelphia Chromosome-positive (Ph+) · condition mapped ALIAS · 8 trials mapped (4 active)	—	—	Poroid Hidradenoma	1	Observed	clinicaltrials	graph →